Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Peri-Transplant Gecacitinib in Myelofibrosis Undergoing Allo-HSCT
NCT07904871Not yet recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Nov 2026
- Primary completion
- Nov 2028
01
Overview
Open-label, single-arm trial of jaktinib in myelofibrosis (MF), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoint: GVHD-Free, Relapse-Free Survival at 12 months. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
jaktinib
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on NCT07904871.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07904871.